Editor's Note A nurse-coordinated prevention program significantly lowered the long-term risk of major adverse cardiovascular events (MACE) in adults recovering from acute coronary syndrome (ACS), according to an April 2 article in Healio. The program, which focused on lifestyle and behavioral changes, led to a 30% reduction in adverse events,…
Editor's Note The Joint Commission announced significant updates taking effect immediately to the eligibility requirements for its cardiac and stroke certifications, developed in collaboration with the American Heart Association (AHA) and the American Stroke Association (ASA). According to the April 2 announcement, key revisions involve the removal of percutaneous coronary…
Editor's Note Aortic root cannulas from Medtronic are the subject of the latest US Food and Drug Administration (FDA) class 1 recall, the most serious category reserved for risk of injury or death. Affected products include the DLP Aortic Root Cannula, MiAR Cannula, and DLP Aortic Root Cannula with Vent…
Editor's Note HST Pathways’ most recent industry report, discussed on the Advancing Surgical Care Podcast by HST CEO David Thawley and Bill Prentice, CEO of the Ambulatory Surgery Center Association (ASCA), offers insights into cardiology and orthopedic procedures done in ambulatory surgery centers (ASCs) in 2024, Ambulatory Surgery Center News…
Editor's Note A wearable smart t-shirt that remotely monitors vital signs helped patients go home earlier and feel safer after robot-assisted urological cancer surgery, according to a March 21 article in Medical Xpress. The article details a pilot study, presented at the European Association of Urology Congress in Madrid, Spain,…
Editor's Note Endovascular devices used to block aneurysm blood flow are the subject of the latest recall to be designated Class 1—the most severe designation indicating serious risk of injury or death—by the US Food and Drug Administration (FDA). As detailed in the agency’s March 18 announcement, Medtronic Neurovascular is…
Editor's Note Miniaturized pacemakers implanted in neonates and infants have demonstrated reliable performance for up to two years, with no unexpected device failures, according to a March 11 article in Healio. The research, published in Circulation: Arrhythmia and Electrophysiology, suggests that these modified pacemakers could offer a viable alternative for…
Editor's Note An Australian man lived for 100 days with an artificial titanium heart, the longest duration recorded for a patient using the device, according to a March 12 report from CNN. The breakthrough marks a significant step toward using total artificial hearts as a long-term solution for patients with…
Editor's Note Surgeons recently performed open-heart surgery on an infant during a C-section to correct a congenital heart defect, according to a February 25 brief from the American College of Surgeons. Led by Dr. Sameh Said at Maria Fareri Children's Hospital, a team of specialists conducted the procedure on a…
Editor’s Note The US Food and Drug Administration (FDA) has designated Boston Scientific Corporation’s recall of Accolade Pacemaker devices a Class 1, the most severe category indicating serious risk of injury or death. According to the agency’s February 21 announcement, the recall was motivated by a manufacturing issue that could…